<DOC>
	<DOCNO>NCT02576977</DOCNO>
	<brief_summary>The purpose study compare efficacy pomalidomide low dose dexamethasone pembrolizumab ( MK-3475 ) pomalidomide low dose dexamethasone without pembrolizumab term Progression-Free Survival ( PFS ) participant refractory relapse refractory multiple myeloma ( rrMM ) undergone least 2 line prior treatment .</brief_summary>
	<brief_title>Study Pomalidomide Low Dose Dexamethasone With Without Pembrolizumab ( MK-3475 ) Refractory Relapsed Refractory Multiple Myeloma ( rrMM ) ( MK-3475-183/KEYNOTE-183 )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Has confirm diagnosis active multiple myeloma measurable disease Must undergone prior treatment ≥2 treatment line antimyeloma therapy must fail last line treatment ( refractory last line treatment ) Prior antimyeloma treatment must include immunomodulatory drug ( IMiD ) AND proteasome inhibitor alone combination participant must fail therapy IMiD OR proteasome inhibitor Has performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Female participant childbearing potential must 2 negative urine human chorionic gonadotropin test within 10 14 day within 24 hour prior receive study medication Female participant childbearing potential male participant must agree use adequate contraception 28 day prior study start continue 28 day last dose pomalidomide ( 120 day last dose pembrolizumab ) Has prior antimyeloma therapy within 2 week prior study start recover ( i.e. , ≤ Grade 1 Baseline ) adverse event due previously administer agent Has undergone prior allogeneic hematopoetic stem cell transplantation within last 5 year . ( Participants transplant great 5 year ago eligible long symptom Graft versus Host Disease [ GVHD ] ) . Has receive autologous stem cell transplant ( autoSCT ) within 12 week first infusion planning eligible autoSCT Has receive previous therapy pomalidomide Has peripheral neuropathy ≥ Grade 2 Has know additional malignancy progress require active treatment within last 5 year ( except basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy ) Has history ( noninfectious ) pneumonitis require steroid current pneumonitis Has receive prior therapy antiprogrammed cell death 1 receptor ( antiPD1 ) , antiprogrammed deathligand 1 ( antiPDL1 ) , antiPDL2 , antiCD137 , anticytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) Is pregnant breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PDL1</keyword>
	<keyword>PD1</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>